Rafferty Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.17M Buy
15,725
+4,364
+38% +$647K 0.01% 608
2026
Q2
$1.74M Sell
11,361
-3,229
-22% -$392K ﹤0.01% 677
2026
Q1
$1.82M Sell
14,590
-1,144
-7% -$119K 0.01% 629
2025
Q4
$1.65M Buy
+15,734
New +$1.34M 0.01% 692
2022
Q3
– Sell
-370
Closed -$55K – 1265
2022
Q2
$55K Buy
370
+90
+32% +$16.4K ﹤0.01% 1097
2022
Q1
$68K Buy
280
+23
+9% +$6.05K ﹤0.01% 1195
2021
Q4
$78K Sell
257
-140
-35% -$44.8K ﹤0.01% 1269
2021
Q3
$164K Buy
+397
New +$138K ﹤0.01% 1199

Other funds holding PVLA

Rafferty Asset Management's PVLA Position: Q3 2026 in Review

Rafferty Asset Management increased its Palvella Therapeutics (PVLA) stake by 38% in Q3 2026, buying an estimated $647K and bringing the position to 15,725 shares worth $2.17M. The position accounts for 0.01% of the portfolio, ranked #608.

Rafferty Asset Management first reported a position in PVLA in Q3 2021 and has held it in 8 quarters since. 199 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • Rafferty Asset Management held 15,725 shares of Palvella Therapeutics worth $2.17M as of Q3 2026.
  • Rafferty Asset Management bought 4,364 Palvella Therapeutics shares in Q3 2026, an estimated $647K.
  • Palvella Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q3 2026, its #608 holding.
  • Rafferty Asset Management first reported a position in Palvella Therapeutics in Q3 2021 and has held it in 8 quarters since.
  • 199 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.